Siemens defies economic pressures with record €120B backlog and 32% EBIT surge
Siemens has demonstrated resilience in a challenging economic climate, with its stock rising by 2.51% since early 2026. Despite a recent 4.1% drop in share price, the company's strong financials and diversified business model continue to attract investors. A record €120 billion order backlog and robust demand for automation solutions have kept performance steady even as energy costs climb.
The conglomerate's financial results for 2026 show significant growth, with EBIT jumping 32.49% to €12.05 billion. This improvement comes from higher margins and efficiency programmes that helped offset rising costs. Siemens' focus on Digital Industries and Smart Infrastructure has driven demand, particularly for automation software and supply chain optimisation, setting it apart from competitors reliant on hardware alone.
However, market volatility has still left its mark. Between early March and March 9, 2026, Siemens' share price fell from around €246 to €220.35, underperforming peers like the EURO STOXX 50, which saw only a minor decline. Daily losses, including a 3.55% drop on March 2 and 1.9% on March 9, reflected broader uncertainty ahead of US economic data and the Federal Reserve's mid-March meeting. Siemens Energy, a separate entity, also faced sharper declines, losing 4.97% on March 13. The company's progressive dividend policy and low debt levels provide stability, allowing flexibility for share buybacks and acquisitions. Diversification across sectors like Mobility and Healthineers further shields it from industry-specific downturns. Even with oil price surges weighing on German manufacturing, Siemens' strong cash flow and backlog offer a buffer against economic pressures.
Siemens' ability to expand margins and maintain a solid balance sheet has reinforced investor confidence. The company's focus on high-growth areas like automation and software, combined with its diversified portfolio, positions it more strongly than many DAX rivals. While short-term market fluctuations remain a risk, its financial strength and strategic direction suggest continued stability.
Read also:
- Federal Funding Supports Increase in Family Medicine Residency Program, Focusing on Rural Health Developments
- Potential Role of DHA in Shielding the Brain from Saturated Fats?
- Alternative Gentle Retinoid: Exploring Bakuchiol Salicylate for Sensitive Skin
- Hanoi initiates a trial program for rabies control, along with efforts to facilitate the transition from the dog and cat meat trade industry.